Biologically relevant conformational features of linear and cyclic proteolipid protein (PLP) peptide analogues obtained by high-resolution nuclear magnetic resonance and molecular dynamics

Proteolipid protein (PLP) is one of the main proteins of myelin sheath that are destroyed during the progress of multiple sclerosis (MS). The immunodominant PLP139–151 epitope is known to induce experimental autoimmune encephalomyelitis (EAE, animal model of MS), wherein residues 144 and 147 are recognized by T cell receptor (TCR) during the formation of trimolecular complex with peptide-antigen and major histocompability complex. The conformational behavior of linear and cyclic peptide analogues of PLP, namely PLP139–151 and cyclic (139–151) (L144, R147) PLP139–151, have been studied in solution by means of nuclear magnetic resonance (NMR) methods in combination with unrestrained molecular dynamics simulations. The results indicate that the side chains of mutated amino acids in the cyclic analogue have different spatial orientation compared with the corresponding side chains of the linear analogue, which can lead to reduced affinity to TCR. NMR experiments combined with theoretical calculations pave the way for the design and synthesis of potent restricted peptides of immunodominant PLP139–151 epitope as well as non peptide mimetics that rises as an ultimate goal.

[1]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[2]  T Mavromoustakos,et al.  Treatment of experimental allergic encephalomyelitis (EAE) by a rationally designed cyclic analogue of myelin basic protein (MBP) epitope 72-85. , 2000, Bioorganic & medicinal chemistry letters.

[3]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[4]  L. Steinman,et al.  Assessment of Animal Models for MS and Demyelinating Disease in the Design of Rational Therapy , 1999, Neuron.

[5]  A. Sette,et al.  Immunogenic and encephalitogenic epitope clusters of myelin proteolipid protein. , 1996, Journal of immunology.

[6]  L Steinman,et al.  Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System , 1996, Cell.

[7]  R. Sobel,et al.  Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. , 1989, Journal of immunology.

[8]  G. Stavropoulos,et al.  2-Chlorotrityl chloride resin. Studies on anchoring of Fmoc-amino acids and peptide cleavage. , 2009, International journal of peptide and protein research.

[9]  Daniel R Roe,et al.  PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. , 2013, Journal of chemical theory and computation.

[10]  A. Sette,et al.  A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. , 1994, Journal of immunology.

[11]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[12]  Jianyin Shao,et al.  Clustering Molecular Dynamics Trajectories: 1. Characterizing the Performance of Different Clustering Algorithms. , 2007, Journal of chemical theory and computation.

[13]  Vasso Apostolopoulos,et al.  Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators. , 2005, Journal of medicinal chemistry.

[14]  Constantinos Potamitis,et al.  Conformational analysis of the ΜΒΡ83–99 (Phe91) and ΜΒΡ83–99 (Tyr91) peptide analogues and study of their interactions with the HLA-DR2 and human TCR receptors by using Molecular Dynamics , 2011, J. Comput. Aided Mol. Des..

[15]  Don C. Wiley,et al.  Crystal Structure of HLA-DR2 (DRA*0101, DRB1*1501) Complexed with a Peptide from Human Myelin Basic Protein , 1998, The Journal of experimental medicine.

[16]  L. Steinman,et al.  The T lymphocyte in experimental allergic encephalomyelitis. , 1990, Annual review of immunology.

[17]  Theodore V. Tselios,et al.  Molecular dynamics at the receptor level of immunodominant myelin basic protein epitope 87-99 implicated in multiple sclerosis and its antagonists altered peptide ligands: triggering of immune response. , 2007, Journal of molecular graphics & modelling.

[18]  V. Kuchroo,et al.  Identification and characterization of a second encephalitogenic determinant of myelin proteolipid protein (residues 178-191) for SJL mice. , 1992, Journal of immunology.

[19]  Simona Golic Grdadolnik,et al.  A combined NMR and molecular dynamics simulation study to determine the conformational properties of agonists and antagonists against experimental autoimmune encephalomyelitis. , 2008, Bioorganic & medicinal chemistry.

[20]  R. Skeel,et al.  Langevin stabilization of molecular dynamics , 2001 .

[21]  B. Weinshenker,et al.  Multiple sclerosis. , 2000, The New England journal of medicine.

[22]  Simona Golic Grdadolnik,et al.  Comparison of proposed putative active conformations of myelin basic protein epitope 87-99 linear altered peptide ligands by spectroscopic and modelling studies: the role of positions 91 and 96 in T-cell receptor activation. , 2006, Journal of medicinal chemistry.

[23]  Theodore V. Tselios,et al.  Use of the 2‐chlorotrityl chloride resin for microwave‐assisted solid phase peptide synthesis , 2015, Biopolymers.

[24]  Harald Schwalbe,et al.  Perspectives on NMR in drug discovery: a technique comes of age , 2008, Nature Reviews Drug Discovery.

[25]  Theodore V. Tselios,et al.  Molecular dynamics at the receptor level of immunodominant myelin oligodendrocyte glycoprotein 35-55 epitope implicated in multiple sclerosis. , 2016, Journal of molecular graphics & modelling.

[26]  H. Benson,et al.  Cyclic peptides as potential therapeutic agents for skin disorders , 2010, Biopolymers.

[27]  Theodore V. Tselios,et al.  Rational Design and Synthesis of Altered Peptide Ligands based on Human Myelin Oligodendrocyte Glycoprotein 35–55 Epitope: Inhibition of Chronic Experimental Autoimmune Encephalomyelitis in Mice , 2014, Molecules.

[28]  Theodore V. Tselios,et al.  Immune responses of linear and cyclic PLP139-151 mutant peptides in SJL/J mice: peptides in their free state versus mannan conjugation. , 2014, Immunotherapy.

[29]  Theodore V. Tselios,et al.  Antagonistic effects of human cyclic MBP(87-99) altered peptide ligands in experimental allergic encephalomyelitis and human T-cell proliferation. , 2002, Journal of medicinal chemistry.

[30]  S. Tenzer,et al.  Myelin Proteomics: Molecular Anatomy of an Insulating Sheath , 2009, Molecular Neurobiology.

[31]  Theodore V. Tselios,et al.  Review cyclic peptides on a merry‐go‐round; towards drug design , 2015, Biopolymers.

[32]  Guangshun Wang,et al.  Solution structure of NPr, a bacterial signal-transducing protein that controls the phosphorylation state of the potassium transporter-regulating protein IIANtr , 2008, Amino Acids.

[33]  N. Yuki,et al.  Guillain-Barré Syndrome Animal Model: The First Proof of Molecular Mimicry in Human Autoimmune Disorder , 2010, Journal of biomedicine & biotechnology.

[34]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[35]  V. Kuchroo,et al.  High Frequency of Autoreactive Myelin Proteolipid Protein–Specific T Cells in the Periphery of Naive Mice , 2000, The Journal of experimental medicine.

[36]  T Mavromoustakos,et al.  Design and synthesis of a potent cyclic analogue of the myelin basic protein epitope MBP72-85: importance of the Ala81 carboxyl group and of a cyclic conformation for induction of experimental allergic encephalomyelitis. , 1999, Journal of medicinal chemistry.

[37]  Georgios A. Dalkas,et al.  Putative bioactive conformations of amide linked cyclic myelin basic protein peptide analogues associated with experimental autoimmune encephalomyelitis. , 2007, Journal of medicinal chemistry.

[38]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[39]  Vasso Apostolopoulos,et al.  Round and round we go: cyclic peptides in disease. , 2006, Current medicinal chemistry.

[40]  H. McFarland,et al.  T cell response to two immunodominant proteolipid protein (PLP) peptides in multiple sclerosis patients and healthy controls , 1996, Multiple sclerosis.